In this section, we will explore the different therapeutic targets identified over time (Figure 3), beginning with the recently discovered PRMT5/methionine adenosyltransferase 2A (MAT2A) axis and then tracing back to earlier targets that have shaped our understanding of MTAP-deleted tumor vulnerabilities. Here, PRMT5 is linked to neoplasm.